<DOC>
	<DOC>NCT01419327</DOC>
	<brief_summary>This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in hemodialysis who received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. A total 3,000 patients will be recruited and followed 5 years.</brief_summary>
	<brief_title>Fosrenol Post-marketing Surveillance for Hemodialysis in Japan</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients undergoing hemodialysis who received Fosrenol for hyperphosphatemia Patients who are contraindicated based on the product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Fosrenol</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Hemodialysis</keyword>
</DOC>